Earlier essays in this collection describe what esketamine treatment is actually like and what TMS treatment is actually like. This one is different in kind: it is a data page, not a narrative one. Two things follow, each pulled from a published source and linked so you can read the original yourself.
A note on how to read this
The cost figures below come from published market and price surveys, not from any single clinic's price list, which is why each is phrased as "published price surveys report" rather than as a fixed number. The response-rate figures come from peer-reviewed clinical research and are described as findings of those specific studies. This page is general education, not medical advice, and nothing here describes the pricing or outcomes of any particular clinic, including Brain Recovery Centers.
What published price surveys report
Esketamine (Spravato) with commercial insurance: published price surveys report that most insured patients pay roughly $10 to $250 per session, and that the manufacturer's savings program can reduce the medication portion to as little as $10 (Healing Maps, 2026). Without insurance, published surveys report retail pricing of roughly $700 to $1,000 per session, or about $4,000 to $8,000 for a first month of eight doses (Bright Horizons Psychiatry, 2026). IV ketamine infusions, used off-label for depression, are reported at $400 to $700 per session and are rarely covered by insurance (Lumin Health, 2026). Published surveys also report that Spravato, the only FDA-approved ketamine-based medicine for depression, is covered by Medicare and most major insurance plans, commonly listing BCBS, UnitedHealthcare, Aetna, Cigna, and Humana (Mindbloom, 2026). And published clinic protocols commonly describe a course of six to ten sessions over three to five weeks for the induction phase (Lumin Health, 2026).
What the clinical research reports
A two-site randomized controlled trial found a 64% response rate to ketamine at 24 hours, compared with 28% for an active placebo (American Journal of Psychiatry, Murrough et al.). A broader review reports published response rates generally between 35% and 60% for low-dose ketamine in treatment-resistant depression, with meta-analytic estimates near 50% response and 28% remission (Psychiatry Research, 2024). An open-label study found a 70.8% response rate after up to six IV infusions given over two weeks (Translational Psychiatry). By contrast, research summarizing the STAR*D era found roughly 27% response and 17% remission at six months after two ineffective antidepressant trials, with about 14% remission as a third-line medication (PMC ketamine review). And response is not universal: one naturalistic inpatient study found 75% of 40 treatment-resistant patients were classified as non-responders to short-term ketamine, a reminder that outcomes vary by protocol and population (Pharmacological Reports, 2025).
These are published averages across studies and markets. They are not a prediction for any one person.
The honest takeaway
What you would actually pay, and how you would actually respond, depend on your insurance, your history, and the specific clinic, none of which a published survey can answer for you. A clinician who knows your case, and a clinic that can check your coverage directly, are the only real sources for those two answers.